Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03972046
Title Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors David Lee
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
TriHealth Cancer Institute - Kenwood Cincinnati Ohio 45236 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field